Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. / Wegener, Henrik Caspar; Aarestrup, Frank Møller; Jensen, Lars Bogø; Hammerum, Anette Marie; Bager, Flemming.

I: Emerging Infectious Diseases (Print Edition), Bind 5, Nr. 3, 1999, s. 329-335.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Wegener, HC, Aarestrup, FM, Jensen, LB, Hammerum, AM & Bager, F 1999, 'Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe', Emerging Infectious Diseases (Print Edition), bind 5, nr. 3, s. 329-335.

APA

Wegener, H. C., Aarestrup, F. M., Jensen, L. B., Hammerum, A. M., & Bager, F. (1999). Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerging Infectious Diseases (Print Edition), 5(3), 329-335.

Vancouver

Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM, Bager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerging Infectious Diseases (Print Edition). 1999;5(3):329-335.

Author

Wegener, Henrik Caspar ; Aarestrup, Frank Møller ; Jensen, Lars Bogø ; Hammerum, Anette Marie ; Bager, Flemming. / Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. I: Emerging Infectious Diseases (Print Edition). 1999 ; Bind 5, Nr. 3. s. 329-335.

Bibtex

@article{6ce063625cd3414482c44f226472f670,
title = "Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe",
abstract = "Supplementing animal feed with antimicrobial agents to enhance growth has been common practice for more than 30 years and is estimated to constitute more than half the total antimicrobial use worldwide. The potential public health consequences of this use have been debated; however, until recently, clear evidence of a health risk was not available. Accumulating evidence now indicates that the use of the glycopeptide avoparcin as a growth promoter has created in food animals a major reservoir of Enterococcus faecium, which contains the high level glycopeptide resistance determinant vanA, located on the Tn1546 transposon. Furthermore, glycopeptide-resistant strains, as well as resistance determinants, can be transmitted from animals to humans. Two antimicrobial classes expected to provide the future therapeutic options for treatment of infections with vancomycin-resistant enterococci have analogues among the growth promoters, and a huge animal reservoir of resistant E. faecium has already been created, posing a new public health problem.",
author = "Wegener, {Henrik Caspar} and Aarestrup, {Frank M{\o}ller} and Jensen, {Lars Bog{\o}} and Hammerum, {Anette Marie} and Flemming Bager",
year = "1999",
language = "English",
volume = "5",
pages = "329--335",
journal = "Emerging Infectious Diseases (Print Edition)",
issn = "1080-6040",
publisher = "CDC Centers for Disease Control and Prevention",
number = "3",

}

RIS

TY - JOUR

T1 - Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe

AU - Wegener, Henrik Caspar

AU - Aarestrup, Frank Møller

AU - Jensen, Lars Bogø

AU - Hammerum, Anette Marie

AU - Bager, Flemming

PY - 1999

Y1 - 1999

N2 - Supplementing animal feed with antimicrobial agents to enhance growth has been common practice for more than 30 years and is estimated to constitute more than half the total antimicrobial use worldwide. The potential public health consequences of this use have been debated; however, until recently, clear evidence of a health risk was not available. Accumulating evidence now indicates that the use of the glycopeptide avoparcin as a growth promoter has created in food animals a major reservoir of Enterococcus faecium, which contains the high level glycopeptide resistance determinant vanA, located on the Tn1546 transposon. Furthermore, glycopeptide-resistant strains, as well as resistance determinants, can be transmitted from animals to humans. Two antimicrobial classes expected to provide the future therapeutic options for treatment of infections with vancomycin-resistant enterococci have analogues among the growth promoters, and a huge animal reservoir of resistant E. faecium has already been created, posing a new public health problem.

AB - Supplementing animal feed with antimicrobial agents to enhance growth has been common practice for more than 30 years and is estimated to constitute more than half the total antimicrobial use worldwide. The potential public health consequences of this use have been debated; however, until recently, clear evidence of a health risk was not available. Accumulating evidence now indicates that the use of the glycopeptide avoparcin as a growth promoter has created in food animals a major reservoir of Enterococcus faecium, which contains the high level glycopeptide resistance determinant vanA, located on the Tn1546 transposon. Furthermore, glycopeptide-resistant strains, as well as resistance determinants, can be transmitted from animals to humans. Two antimicrobial classes expected to provide the future therapeutic options for treatment of infections with vancomycin-resistant enterococci have analogues among the growth promoters, and a huge animal reservoir of resistant E. faecium has already been created, posing a new public health problem.

M3 - Journal article

VL - 5

SP - 329

EP - 335

JO - Emerging Infectious Diseases (Print Edition)

JF - Emerging Infectious Diseases (Print Edition)

SN - 1080-6040

IS - 3

ER -

ID: 172809114